Navigation Links
Mpex Pharmaceuticals Names Mark Wiggins Chief Business Officer
Date:4/20/2009

harmaceuticals. "His deep experience in marketing will be key to us as we move towards commercialization with MP-376 and his expertise in structuring and managing complex collaborations will be invaluable as we are evaluating strategic commercialization options."

"I am excited to be joining Mpex at this critical time in the company's development," said Mark Wiggins. "I am very impressed with the progress Mpex has made in such a short time and believe there is a significant opportunity for MP-376 to become a therapy which can improve the quality of lives for patients suffering from cystic fibrosis or COPD. Exacerbations remain a significant problem in both of these diseases and MP-376 holds the promise of reducing the frequency of these events. As Mpex has retained global rights to MP-376 and the conclusion of the Phase II trials nears, I look forward to working with the rest of the management team to help Mpex achieve full potential for this new product opportunity."

About Mpex Pharmaceuticals

Mpex Pharmaceuticals is a clinical stage biopharmaceutical company whose mission is to develop important new therapies to combat the growing issue of antibiotic resistance. The company's internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacteria responsible for antibiotic resistance. Mpex's most advanced product candidate, MP-376, is a proprietary aerosol formulation of levofloxacin for nebulization that is being developed clinically as a maintenance therapy for the prevention of exacerbations in patients with cystic fibrosis and COPD. MP-376 is currently in Phase 2 studies for both indications. The company has also built a discovery and development platform and intellectual property estate around inhibitors of multi-drug resistant (MDR) efflux pumps (EPIs) found in m
'/>"/>

SOURCE Mpex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
2. Sunesis Pharmaceuticals Receives NASDAQ Notification
3. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
4. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
5. Accera, Inc. Launches Neuera Pharmaceuticals, Inc.
6. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
7. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
8. Marinus Pharmaceuticals Raises $20 Million in Series B Financing
9. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
10. Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008
11. Gemin X Pharmaceuticals Selects and Deploys Clinical Force CTMS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015  Prima Biomed Ltd. ... that is striving to become a leader in the ... recently announced that the final CVac data from the ... a clear trend for a clinically meaningful improvement in ... second remission patients. In the group of ...
(Date:5/21/2015)... Imagine being able to probe and truly ... Being able to read faces and enjoy genuine invisible ... their thoughts and actions like never before. Use ... unique abstract paintings and video, or, play a completely ... as it creates action, dialog, and outcomes based on ...
(Date:5/21/2015)...  CytRx Corporation (NASDAQ: CYTR ), a ... today announced positive updated results from its ongoing ... treatment of unresectable glioblastoma multiforme (GBM), a deadly ... is designed to investigate the preliminary efficacy and ... progressed following prior treatment with surgery, radiation and ...
(Date:5/21/2015)... - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: ... on the development of autologous cell therapies, announced ... Society for Cellular Therapy (ISCT) on RepliCel,s autologous ... a Phase 1/2 clinical trial.  The presentation, taking ... PM to 7:00 PM local time, will review ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 25 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3
... Va., June 27, 2011 A Continuing Medical Education (CME) ... of key risk factors , will be hosted at the ... 2011 from 8:30am to 1pm. "Beating ... Education credits, is designed to help doctors eradicate this disease ...
... JUPITER, Fla., June 27, 2011 Dyadic International, ... company focused on the discovery, development, manufacture and ... industrial enzyme, bioenergy, and biopharmaceutical industries, announced today ... development and license agreement with a key provider ...
... PharmacoFore, Inc., a privately held biopharmaceutical company developing ... Dr. Joseph Stauffer as Chief Medical Officer & VP, ... Property. Dr. Joseph Stauffer ... Prior to joining PharmacoFore, Dr. Stauffer ...
Cached Biology Technology:Health Diagnostic Laboratory Inc. Sponsors Lecture Series in West Palm Beach, Florida 2Dyadic International Enters Into Research and License Agreement With Major Player in the Animal Feed Industry 2Dyadic International Enters Into Research and License Agreement With Major Player in the Animal Feed Industry 3PharmacoFore, Inc. Announces Appointment of Chief Medical Officer and Vice President of Intellectual Property 2PharmacoFore, Inc. Announces Appointment of Chief Medical Officer and Vice President of Intellectual Property 3PharmacoFore, Inc. Announces Appointment of Chief Medical Officer and Vice President of Intellectual Property 4
(Date:5/19/2015)... , May 19, 2015  Technology is rapidly ... internally and in the cloud. Passwords and their management ... of OTP and standards-based specifications such as those developed ... outmoded use of passwords presents for BYOD, COPE, IoT, ... unified biometric identity protocol. In response ...
(Date:5/14/2015)... and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) has announced ... Smart Mobile Devices " report to their offering. ... watershed year for fingerprint sensors in smartphones and tablets, ... fingerprint sensors a raison d,etre in the mobile milieu ... must-have feature in flagship smartphones. The key ...
(Date:5/11/2015)...  Through a well-rounded UAS delegation representing private industry, government, ... showing at AUVSI,s Unmanned 2015 conference last week in ... UAS industry met with over 200 hundred people ... the UAS ecosystem. "Our message is clear ... Aerospace Rich Knoll . "If you want to fly ...
Breaking Biology News(10 mins):HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... the University of Houston for a two-day conference to discuss ... , The UH Texas Obesity Research Center (TORC) ... UH M.D. Anderson Library, Rockwell Pavilion. , "We ... that others will see the wealth of obesity research that ...
... hopeful moms-to-be learn, there are important considerations to the ... environment, regular hormonal injections and the timing of the ... procedure. Now a Tel Aviv University researcher ... look at the role that gravity and other biomechanical ...
... team of scientists led by the UK has been given ... frontiers - an ancient lake hidden deep beneath Antarctica,s ice ... the size of Lake Windermere (UK) may have been ... unique forms of life. The team hopes the exploration will ...
Cached Biology News:Texas Obesity Research Center at UH assembles researchers to discuss obesity 2Engineering bouncing babies, 1 at a time 2Final frontier: Mission to explore buried ancient Antarctic lake given green light 2
... The European Collection of Cell Cultures (ECACC) ... West of the West of England, Bristol, ... the quality control of HER2, oestrogen and ... paraffin wax sections of formalin fixed, breast ...
... Electro-4 design allows "4 gels in one ... possible to run 200,samples or more in ... to four,horizontal gels. To ensure even migration, ... number of gels being run. Ideal for,high ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
... several isoprostanes produced from arachidonic acid during lipid ... the rat. 8-iso PGE2 inhibits U-46619 or I-BOP-induced ... 5 µM, respectively. When infused into the renal ... 4 mg/kg/min, 8-iso PGE2 decreases the GFR and ...
Biology Products: